The French biopharmaceutical company, PLL Therapeutics, announced positive results from a phase I/II clinical trial for its investigational therapy PLL001 to treat amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that causes degeneration of motor neurons and loss of muscle control.
Belgian Imec researchers have presented a prototype of an ingestible sensor for long-term gut health monitoring that is able to measure acidifidation that is linked to gut inflammation.
A bacterium of the gut microbiome seems to spark an autoimmune disease in the kidneys by leaking antigens that trigger the immune system.
Imec